Role of additional dexamethasone for the management of persistent or recurrent neovascular age-related macular degeneration under ranibizumab treatment
Conclusion: This pilot study indicates combined therapy to delay retreatment in patients with persistent/recurrent neovascular age-related macular degeneration and an overall reduction in required ranibizumab retreatments compared with ranibizumab monotherapy with consistent functional outcomes.
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Cataract Removal | Cataracts | Dexamethasone | Diabetes | Endocrinology | Eye Implants | Eyes | Lucentis | Ranibizumab Injection | Study